S. Treon, C. Buske, S. Thomas
Jun 1, 2021
Citations
0
Influential Citations
2
Citations
Quality indicators
Journal
Hematological Oncology
Abstract
No AEs led to study discontinuation, and no serious AEs were observed. Six of 7 patients showed IgM decrease after 1 cycle. Four patients received ≥ 3 cycles; all had IgM decrease, with 2 achieving ≥ 50% decrease consistent with partial response (median decrease, 51.0%; range, 4.4%–84.5%). Mavorixafor and ibrutinib exposures were consistent with previous single ‐ agent studies, and combination treatment increased WBCs. Conclusions: Our findings to date in patients with WM carrying both MYD88 and CXCR4 mutations show that mavorixafor in combination with ibrutinib is well tolerated at doses ≤ 400 mg QD. Un-altered mavorixafor and ibrutinib exposures suggest no apparent drug–drug interaction, and mavorixafor exposures tracked with increased WBC counts. Combination of mavorixafor with ibrutinib led to rapid and clinically meaningful decrease in IgM, suggesting mavorixafor may sensitize CXCR4 WHIM ‐ expressing cells to BTKi. submitted